If you are concerned about a zombie apocalypse or harbor some anxieties after watching too much The Walking Dead, well you should know that unwarranted fear just got a smidgen closer to actual reality. As with any science experimentation on unconsenting humans, questions of ethics and abuse certainly arise. That said, these companies have been given the stamp of approval to proceed after an ethical review. She shall see how it ends, folks.
Two Biotech companies, Bioquark, Inc., (http://www.bioquark.com) and Revita Life Sciences, (http://revitalife.co.in), have been granted ethical permission and approval by the IRB for a study for clinical intervention in the brain dead. The company plans to stimulate the brain dead’s nervous systems to what they call, restart their brains. What sounds like that of a sci-fi movie script is now becoming reality.
A team of researchers plans to test individuals declared to be formally brain dead and have been kept on life support machines, which have kept their bodies from decomposing. They will be injecting their brains with stem cells. They will also attempt spinal cord infusions and nerve stimulations. The process could take takes months to determine validity. As each brain dead patient is subjected to the experiments, the research team will then watch the patient for months to see if any reactions or stimulations transpire.
After brain death, neurons, which can be typically stimulated by electricity, die off resulting in a lesser opportunity for revival. The essence of these experiments is to regenerate those neurons and then infuse activity once again. This is the juncture which stem cells would be used. According to IFLScience, this is a “bridge to eventuality.”
In any case, the trials will begin at Anupam Hospital in Rudrapur, Uttarakhand in India. For this stage, the brain-dead people will be continuously given cocktails of peptides, chemicals that can act as neurotransmitters, along with biweekly injections of stem cells.
“It is a long-term vision of ours that a full recovery in such patients is a possibility, although that is not the focus of this first study,” Pastor added. “But it is a bridge to that eventuality.”
You can read the corporate press release here.
— IraSamuel Pastor (@IraSamuelPastor) April 20, 2016